TSO3 Inc

TSO3 — Investor Presentation (September 2017)

29 slides from TSO3's investor presentation, Sep 28, 2017

  1. Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing

    To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation | September 2017 1

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward-looking statements that involve certain risks

  3. Slide 3: Vision and Purpose: A Sterile Device for Every Procedure

    VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Procedure 3

  4. Slide 4: Major Milestones Laying Foundation for Growth

    Major Milestones Laying Foundation for Growth 1998 - 2008 2009-2014 2015 2016 2017 • Founded • Product redesign • Exclusive distribution • Shipped 110 STERIZONE® • TTM Revenue of agreement with Getinge VP4 Sterilizers to Getinge $16.1M1 • HQ: Québec City, • Introduced - $7.5M in cash + Canada STERIZ

  5. Slide 5: STERIZONE VP4 Sterilizer

    STERIZONE VP4 Sterilizer ® Advantages • Single cycle – easy, error-free cycle selection • Mixed load sterilization • Up to 75 Ib in a single load • Flexible Endoscope Clearance Proprietary Consumables (Razor/Razorblade Model) • 125-280 Solution™ (H2O2) • STERIZONE® BI+ / Test Pack advanced process m

  6. Slide 6: Industry First: FDA Clearance of TSO3 Endoscope Claims

    Industry First: FDA Clearance of TSO3 Endoscope Claims CLEARED Video Colonoscope The only FDA cleared device validated to sterilize colonoscopes, gastroscopes and other flexible endoscopes up to 3.5m in length and with four or fewer channels. Video Gastroscope TSX:TOS TSX:TOS 6

  7. Slide 7: Breakthrough Technologies: Patents and Patents Pending Worldwide

    Breakthrough Technologies /// 138 Patents + 47 Patents Pending Worldwide 1. Insert Room Temperature Instruments Into a Warm Chamber 2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time 3. Micro Condensation Forms on the Instruments Dynamic Sterilant Delivery SystemTM

  8. Slide 8: Global Market Opportunity

    Global Market Opportunity United States • ~ 10,000 Hospitals and Ambulatory Surgery Centers1 • ~ 48 million annual procedures1 • ~ 15 million colonoscopies performed annually2 • > 500,000 endoscopic retrograde cholangiopancreatographies performed annually 3 Canada • ~ 1,400 Hospitals4 • ~ 2.4 millio

  9. Slide 9: Aging Population – Driving Growth in MIS

    Aging Population – Driving Growth in MIS Minimally Invasive Driving Growth in MI Surgeries and Endoscopies Surgery (MIS) Growth in U.S. Population Age Groups 65+1 90,000,000 • Effective 80,000,000 • Faster Recovery 70,000,000 • More profitable 60,000,000 50,000,000 40,000,000 Over 65 Years Old 30,00

  10. Slide 10: Surgical – OR Support and Diagnostic – GI

    Health Care Procedures Surgical – OR Support • $6b+ Sterilization Existing Market1 • High Growth Low Temperature Component Millions of Surgical and Diagnostic Procedures Each Year Diagnostic – GI • 50m+ Procedures/year2 • No sterilization for most 1) Market and Market, June 2016 2 )Becker’s GI & End

  11. Slide 11: OR Market: Sterile Devices

    OR Market: Sterile Cost Effectiveness Devices Convenience/Simplicity Throughput TSX:TOS 11

  12. Slide 12: A Better Solution for OR Support

    A Better Solution for OR Support Old Technology TSO3 Technology • 20+ year-old core • Next generation industry technology technology • Single sterilant • Dual Sterilant • Fixed delivery • Dynamic Delivery • Small loads • Simple Single Cycle Operation • Segregated loads • Large Loads • Expensive Ster

  13. Slide 13: Larger, Mixed Loads

    Larger, Mixed Loads Competition VS STERIZONE® VP4 Sterilizer TSX:TOS 13

  14. Slide 14: Surgical – OR Support and Diagnostic – GI

    Health Care Procedures Surgical – OR Support • $6b+ Sterilization Existing Market1 • High Growth Low Temperature Component Millions of Surgical and Diagnostic Procedures Each Year Diagnostic – GI • 50m+ Procedures/year2 • No sterilization for most 1) Market and Market, June 2016 2 )Becker’s GI & End

  15. Slide 15: Diagnostic GI/Endoscopic Market Driver

    Diagnostic GI/Endoscopic Market Driver A Shift to a New Standard of Care: Patient Safety TSX:TOS 15

  16. Slide 16: How Change Happens

    How Change Happens Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation • Cost Reduction Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 16

  17. Slide 17: Modernizing GI Endoscope Reprocessing

    Modernizing GI Endoscope Reprocessing Old TSO3 STERIZONE® VP4 Sterilizer TSX:TOS 17

  18. Slide 18: Not Sterile – Why? Spaulding Classification

    Not Sterile – Why? Spaulding Classification TSX:TOS 18

  19. Slide 19: A New Problem: Endoscopes and Superbugs

    A New Problem: Endoscopes and Superbugs “Deaths from Drug-Resistant Infections Set to Skyrocket” Deaths from antimicrobial resistant infections and other causes in 20501 Two million+ Americans suffer Carbapenem-resistant CRE infections are linked to Inadequately-cleaned endoscopes annually from anti

  20. Slide 20: Duodenoscopes – the point on the spear

    Duodenoscopes – the point on the spear Duodenoscope Expanded Claims: FDA – Duodenoscopes • Already cleared in Canada and Europe • Launched US regulatory filings for duodenoscopes Market Launch and Awareness • Duodenoscopes now being terminally sterilized in Western Canada • Working with US and Canad

  21. Slide 21: Public Awareness

    Public Awareness Nation World Los Angeles Times HealthLeaders Media “FDA links ‘superbug‘ to key medical device.” “Jury orders Olympus to pay $6.6 million “Infection fears prompt Fujifilm but rejects claims its medical scopes are Medical Systems Duodenoscopes “LOS ANGELES — A ‘superbug‘ outbreak uns

  22. Slide 22: Industry Call-to-Action

    Industry Call-to-Action “Despite reprocessing in accordance with US “…Despite adherence to strict “We have to transition to sterilization. That guidelines, viable microbes and biologic debris guidelines…bacteria can at times remain on is the only way we’ll eliminate the persisted in clinically used

  23. Slide 23: Shift is Happening

    Shift is Happening Dirty Endoscopes Raising A 21st Century Nosocomial Deadly Bacteria On Seattle Hospital Sues Alarms for Colonoscopies Issue With Endoscopes Medical Scopes Trigger Olympus Over Superbug Infections Outbreak 2009 2013 2014 2014 2015 2015 2015 2015 2015 VA Officials Get Probed For Dirt

  24. Slide 24: Shift is Happening

    Shift is Happening Cross-contamination More Infections Dirty Endoscopes An Epidemic Is On Hospitals Failing to Not Limited to From Contaminated Top ECRI Institute's the Rise That May Report Outbreaks Duodenoscopes Scopes Suspected in 2016 Technology Kill More People Due to Contaminated L.A. Hazards

  25. Slide 25: Shift is Happening

    Shift is Happening Why It Took Years For The Superbug Infections Must Redesigned Olympus Carbapenem-Resistant FDA to Warn About Be Listed On Death Scopes linked to Superbug Enterobacteriaceae in Patients From Infections Tied to Medical Certificate Under Proposed Outbreak: 7 Things to the US Veterans

  26. Slide 26: Commercialization

    Commercialization Joacim Lindoff President of Surgical Workflows Getinge Group • Getinge Group - Exclusive Global Distributor • Global sales and service; 3,000+ associates in 36 countries “The STERIZONE® VP4 Sterilizer uniquely • Paid $7.5 million up-front license fee addresses an unmet global need

  27. Slide 27: Summary

    Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Business Model FDA-cleared Device for Terminal Sterilization of Colonoscopes SUMMARY and other flexible endoscopes Global Distribution Partner Growing Sales Financially Sound TSX:TOS 27

  28. Slide 28: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise Stock Price (9/7/17) CAD$2.52 Quarterly Revenue Growth 52 Week High-Low CAD$3.73-$2.05 US$ Millions $4.6 Shares Outstanding (mrq) (no warrants) 92.7M $4.2 Average Daily Volume (90 day) 220,269 $3.7 Market Capitalization CAD$233M $3.

  29. Slide 29: T Sh,

    T Sh,

TSO3 — Investor Presentation (September 2017) on 6ix